Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: A randomised phase II trial

被引：12
|
作者：
De Ruysscher, Dirk
Bussink, Johan
Rodrigus, Patrick
Kessels, Alfons
Dirx, Miranda
Houben, Ruud
Wanders, Rinus
机构：
[1] Univ Hosp Maastricht, Dept Radiat Oncol, GROW, NL-6229 ET Maastricht, Netherlands
[2] MAASTRO Clin, Maastricht, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands
[4] Bernard Verbeeten Inst, Tilburg, Netherlands
[5] Univ Hosp Maastricht, Dept Hlth Technol Assessment, Maastricht, Netherlands
[6] Comprehens Canc Ctr Limburg, Maastricht, Netherlands
来源：
RADIOTHERAPY AND ONCOLOGY | 2007年 / 84卷 / 01期
关键词：
COX-2; celecoxib; randomised; phase II; NSCLC; radiotherapy;
D O I：
10.1016/j.radonc.2007.05.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In several pre-clinical models, cyclooxygenase (COX) inhibitors increase radio-sensitivity of tumours, whilst not affecting normal tissues. A randomised phase II trial comparing concurrent radiotherapy with either celecoxib or placebo in patients with stage II-III non-small cell lung cancer was therefore initiated. Because of poor recruitment, the study was stopped after the enrollment of 41 patients, instead of the foreseen 102. None of the endpoints differed significantly between both groups. However, due to the limited number of patients, no definitive conclusions can be drawn. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：23 / 25
页数：3
相关论文
共 50 条
  • [1] A Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Unresectable Stage III Non-Small Cell Lung Cancer
    Durm, Greg
    Hanna, Nasser
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S569 - S570
  • [2] Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer
    Goh, BC
    Lehnert, M
    Lim, HL
    Ng, AWK
    Chan, CC
    Kong, HL
    Lee, SC
    Wee, J
    Chua, ET
    Wong, JEL
    ACTA ONCOLOGICA, 2000, 39 (02) : 225 - 229
  • [3] A RANDOMISED PHASE II TRIAL OF OLAPARIB MAINTENANCE VERSUS PLACEBO MONOTHERAPY IN PATIENTS WITH CHEMOSENSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Fennell, Dean
    Casbard, Angela
    Lester, Jason
    Bridges, Sarah
    Griffiths, Gareth
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S894 - S895
  • [4] Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer
    Hong, Tao
    Sun, Teng
    Zhang, Miao
    Liu, Xinlong
    Yuan, Yanliang
    Dolo, Ponnie Robertlee
    Chen, Bi
    Zhang, Hao
    THORACIC CANCER, 2021, 12 (20) : 2796 - 2802
  • [5] A phase I/II trial of concurrent chemo-radiation with dose-escalated radiotherapy in patients with stage II or stage III non-small cell lung cancer
    Landau, D. B.
    Miles, E.
    Illsley, M.
    Laurence, V.
    Hughes, S.
    Ngai, Y.
    Hughes, L.
    Khan, I.
    Mayles, H.
    Mayles, P.
    Fenwick, J.
    LUNG CANCER, 2013, 79 : S64 - S65
  • [6] SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status
    Maguire, J.
    Khan, I.
    McMenemin, R.
    O'Rourke, N.
    McNee, S.
    Kelly, V.
    Peedell, C.
    Snee, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (17) : 2939 - 2949
  • [7] Predictors for pneumonitis for stage II-III non-small cell lung cancer after definitive radiotherapy
    Xu, Xiaohong
    He, Jian
    RADIOTHERAPY AND ONCOLOGY, 2024, 197 : S212 - S213
  • [8] Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial
    Hoppe, Bradford S.
    Nichols, Romaine C.
    Flampouri, Stella
    Pankuch, Mark
    Morris, Christopher G.
    Pham, Dat C.
    Mohindra, Pranshu
    Hartsell, William F.
    Mohammed, Nasiruddin
    Chon, Brian H.
    Kestin, Larry L.
    Simone, Charles B.
    Simone, Charles B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (04): : 732 - 741
  • [9] Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.
    Komaki, R.
    Blumenschein, G. R.
    Wistuba, I. I.
    Lee, J. J.
    Allen, P.
    Wei, X.
    Welsh, J.
    O'Reilly, M.
    Herbst, R. S.
    Tang, X.
    Meyn, R.
    Liu, D.
    Hong, W. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial
    Matsubara, Taichi
    Yamaguchi, Masafumi
    Shimokawa, Mototsugu
    Okamoto, Isamu
    CLINICAL LUNG CANCER, 2024, 25 (03) : 280 - 283
12345